Jump to content
AMCP Learn
Search
Open menu
Cart
AMCP Learn login
Register
Bookmark/Search this post
Facebook
X
LinkedIn
Forward
Home
Catalog
Training Programs
Webinars
Help
Contact Us
FAQ
Who is AMCP?
You are here
Home
Search
An Acute Treatment Option for Migraine: Evidence Across Clinically Relevant Subgroups
Innovations in Lipid Management: Integrating Emerging and Pipeline Therapies
Clinical Updates in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
An Update on a CGRP Receptor Antagonist for the Preventive Treatment of Migraine
Oncology Pipeline 2026: Advances, Trends, and Impact
Precision at Scale: Translating the Evolving Biomarker Landscape in NSCLC Into Strategies for Timeline and Targeted Care
Post-Election Health Policy Outlook
The Evolving Role of Patient Experience Data in Formulary and Coverage Decision-Making
Spotlight on 6.0: The Updated AMCP Format for Formulary Submissions
Beyond Symptoms: Understanding the Right Heart in PAH
(R4) Payer Evidence and Decision-Making in Rare vs. Common Disease Products
(D5) Integrating Perimenopause and Menopause Care into the Pharmacy Benefit: A Managed Care Framework for Improving Women’s Heal
(F5) Ahead of the Curve: Emerging Specialty Therapies and Managed Care Readiness
(L5) The Commissioner's National Priority Voucher (CNPV) Pilot One Year Later: Real-World Approvals and Managed Care Impact
(R5) The Intersection of Population Health and Managed Care Pharmacy: Building Programs That Measure What Matters
(W5) Human Intelligence in the Age of AI: Ensuring Trust and Rigor across Real-World Evidence Lifecycle
(D6) Mind the Gap: Bridging Pharmacy and Medical Benefits to Optimize Biosimilar Value
(M6) The New Economics of Health Plan Pharmacy
(R6) From Pipeline to Patient: Navigating the Next Wave of Cell & Gene Therapies
(K2) The AI Debate: Advancing Humanity or Undermining It?
(K3) Oncology Pipeline 2026: Advances, Trends, and Impact
(K1) America's Next Top Model?
(D4) A Clinical Update on Secondary Cardiovascular Disease Risk Factors and Risk Management
(F4) Precision at Scale: Translating the Evolving Biomarker Landscape in NSCLC Into Strategies for Timely and Targeted Care
(L4) Beyond Price Negotiation: Has Maximum Fair Price (MFP) Reshaped Formulary Dynamics?
Pages
1
2
next ›
last »
Search
Home
Catalog
Training Programs
Webinars
Help
Contact Us
FAQ
Who is AMCP?